MXPA03002296A - Isoxazoles y su uso como inhibidores de erk. - Google Patents
Isoxazoles y su uso como inhibidores de erk.Info
- Publication number
- MXPA03002296A MXPA03002296A MXPA03002296A MXPA03002296A MXPA03002296A MX PA03002296 A MXPA03002296 A MX PA03002296A MX PA03002296 A MXPA03002296 A MX PA03002296A MX PA03002296 A MXPA03002296 A MX PA03002296A MX PA03002296 A MXPA03002296 A MX PA03002296A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- inhibitors
- erk
- isoxazoles
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23295600P | 2000-09-15 | 2000-09-15 | |
| PCT/US2001/028790 WO2002022610A1 (en) | 2000-09-15 | 2001-09-14 | Isoxazoles and their use as inhibitors of erk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03002296A true MXPA03002296A (es) | 2003-06-06 |
Family
ID=22875248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03002296A MXPA03002296A (es) | 2000-09-15 | 2001-09-14 | Isoxazoles y su uso como inhibidores de erk. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US6495582B1 (es) |
| EP (1) | EP1317453B1 (es) |
| JP (1) | JP4052573B2 (es) |
| AT (1) | ATE335737T1 (es) |
| AU (1) | AU2001290940A1 (es) |
| CA (1) | CA2422376A1 (es) |
| DE (1) | DE60122176T2 (es) |
| ES (1) | ES2269458T3 (es) |
| HK (1) | HK1052934B (es) |
| HU (1) | HUP0302991A3 (es) |
| IL (1) | IL154710A0 (es) |
| MX (1) | MXPA03002296A (es) |
| NO (1) | NO325089B1 (es) |
| NZ (1) | NZ525016A (es) |
| WO (1) | WO2002022610A1 (es) |
| ZA (1) | ZA200301696B (es) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5467699A (en) * | 1998-08-07 | 2000-02-28 | Chiron Corporation | Substituted isoxazole as estrogen receptor modulators |
| US20020142982A1 (en) * | 1999-09-02 | 2002-10-03 | Timothy Hla | Method for regulating angiogenesis |
| WO2002014271A1 (fr) * | 2000-08-10 | 2002-02-21 | Mitsubishi Pharma Corporation | Dérivés de proline et leur utilisation comme médicaments |
| US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002022605A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6989385B2 (en) * | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6589997B2 (en) * | 2001-06-29 | 2003-07-08 | North Shore-Long Island Jewish Health System | Small-molecule modulators of hepatocyte growth factor/scatter factor activities |
| JP4342939B2 (ja) | 2001-08-03 | 2009-10-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾール誘導キナーゼインヒビターおよびその使用 |
| NZ530782A (en) * | 2001-08-06 | 2005-11-25 | Pharmacia Italia S | Aminoisoxazole derivatives active as kinase inhibitors |
| RU2004126671A (ru) * | 2002-02-06 | 2005-04-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Гетероарилсоединения, полезные в качестве ингибиторов gsk-3 |
| US20040009981A1 (en) * | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
| MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| WO2004000318A2 (en) | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
| EA200500299A1 (ru) | 2002-08-02 | 2005-08-25 | Вертекс Фармасьютикалз Инкорпорейтед | Пиразольные композиции, используемые в качестве ингибиторов gsk-3 |
| US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| EP2194058B1 (en) | 2002-09-04 | 2013-11-27 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidines suitable for the treatment of cancer diseases |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US7605155B2 (en) | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| MXPA05002571A (es) | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
| US8673924B2 (en) | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| WO2004072029A2 (en) * | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
| DE602004012578T2 (de) * | 2003-08-15 | 2008-12-11 | Vertex Pharmaceuticals Inc., Cambridge | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen |
| CN1902193B (zh) * | 2003-12-04 | 2011-07-13 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的喹喔啉 |
| WO2006011136A2 (en) * | 2004-07-26 | 2006-02-02 | Ben Gurion University Of The Negev Research And Development Authority | Novel naphthoquinone derivatives and uses thereof |
| US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
| SG164378A1 (en) | 2005-02-17 | 2010-09-29 | Synta Pharmaceuticals Corp | Compounds for the treatment of proliferative disorders |
| WO2007022384A2 (en) * | 2005-08-18 | 2007-02-22 | Vertex Pharmaceuticals Incorporated | Pyrazine kinase inhibitors |
| DE602006003777D1 (de) | 2005-09-19 | 2009-01-02 | Hoffmann La Roche | Isoxazolderivate als inverse gaba a alpha5 agonisten |
| AR056206A1 (es) | 2005-10-06 | 2007-09-26 | Schering Corp | Pirazolpirimidinas como inhibidores de protein quinasas |
| CN101316847A (zh) | 2005-10-06 | 2008-12-03 | 先灵公司 | 用作蛋白激酶抑制剂的吡唑并(1,5a)嘧啶化合物 |
| NZ594383A (en) * | 2005-11-03 | 2013-05-31 | Vertex Pharma | Aminopyrimidines useful as kinase inhibitors |
| KR20080074963A (ko) | 2005-11-10 | 2008-08-13 | 쉐링 코포레이션 | 단백질 키나제 억제제로서의 이미다조피라진 |
| US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
| KR101394245B1 (ko) * | 2005-12-30 | 2014-05-14 | 에스케이바이오팜 주식회사 | 아이속사졸 유도체 및 이의 용도 |
| KR20080103996A (ko) | 2006-02-16 | 2008-11-28 | 쉐링 코포레이션 | Ｅｒｋ 억제제로서 피롤리딘 유도체 |
| US7842836B2 (en) | 2006-04-11 | 2010-11-30 | Ardea Biosciences | N-aryl-N'alkyl sulfamides as MEK inhibitors |
| CA2649122C (en) * | 2006-04-18 | 2015-06-30 | Ardea Biosciences, Inc. | Pyridone sulfonamides and pyridone sulfamides as mek inhibitors |
| US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| WO2008054702A1 (en) | 2006-10-31 | 2008-05-08 | Schering Corporation | Anilinopiperazine derivatives and methods of use thereof |
| JP5103604B2 (ja) | 2006-10-31 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインキナーゼ阻害剤としての２−アミノチアゾール−４−カルボン酸アミド |
| MX2009004791A (es) | 2006-10-31 | 2009-08-19 | Schering Corp | Derivados de anilinopiperazina t metodos de uso de los mismos. |
| NZ576750A (en) * | 2006-11-02 | 2012-01-12 | Vertex Pharma | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
| EP2099787B1 (en) * | 2006-12-19 | 2010-07-21 | Vertex Pharmaceuticals, Inc. | Aminopyrimidines useful as inhibitors of protein kinases |
| CN101663295B (zh) * | 2007-03-09 | 2014-11-05 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的氨基嘧啶类化合物 |
| NZ579483A (en) | 2007-03-09 | 2012-07-27 | Vertex Pharma | Aminopyridines useful as inhibitors of protein kinases |
| RU2009137390A (ru) * | 2007-03-09 | 2011-04-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Аминопиримидины, пригодные в качестве ингибиторов протеинкиназ |
| MX2009011059A (es) | 2007-04-13 | 2009-11-26 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasas. |
| US8509487B2 (en) * | 2007-04-19 | 2013-08-13 | Avago Technologies General Ip (Singapore) Pte. Ltd. | System and method for optically measuring a parameter of an object |
| AU2008247594A1 (en) * | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| JP5389785B2 (ja) * | 2007-05-02 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤として有用なチアゾールおよびピラゾール |
| MX2009011811A (es) * | 2007-05-02 | 2010-01-14 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasa. |
| JP2010528021A (ja) * | 2007-05-24 | 2010-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼのインヒビターとして有用なチアゾールおよびピラゾール |
| EP2178861B1 (en) | 2007-07-19 | 2014-08-20 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
| NZ582879A (en) * | 2007-07-31 | 2012-03-30 | Vertex Pharma | Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
| AU2008293542B9 (en) | 2007-08-27 | 2014-08-07 | Dart Neuroscience (Cayman) Ltd. | Therapeutic isoxazole compounds |
| WO2009058728A1 (en) | 2007-10-29 | 2009-05-07 | Schering Corporation | Thiazole derivatives as protein kinase inhibitors |
| MY152271A (en) | 2008-02-21 | 2014-09-15 | Merck Sharp & Dohme | Novel compounds that are erk inhibitors |
| US20110160256A1 (en) * | 2008-06-26 | 2011-06-30 | Rouse Meagan B | Inhibitors of akt activity |
| KR20110050549A (ko) * | 2008-09-03 | 2011-05-13 | 버텍스 파마슈티칼스 인코포레이티드 | 공-결정 및 이를 포함하는 제약 제제 |
| EP2470183B1 (en) | 2009-08-26 | 2015-09-16 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
| AU2011285611B2 (en) | 2010-08-05 | 2014-10-02 | Case Western Reserve University | Inhibitors of ERK for developmental disorders of neuronal connectivity |
| WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
| HUE051096T2 (hu) | 2012-04-26 | 2021-03-01 | Massachusetts Gen Hospital | Ágensek és módszerek a sebészeti keratózis kezelésére és megelõzésére |
| ES2661394T3 (es) * | 2012-07-16 | 2018-03-28 | Neuropore Therapies, Inc. | Derivados de di- y tri-heteroarilo como inhibidores de la agregación de proteínas |
| WO2014186663A2 (en) * | 2013-05-17 | 2014-11-20 | The General Hospital Corporation | Methods for detecting and treating variants of seborrheic keratoses |
| EP3024457A4 (en) | 2013-07-26 | 2017-06-28 | Update Pharma Inc. | Compositions to improve the therapeutic benefit of bisantrene |
| WO2015041533A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
| AU2015328411C1 (en) | 2014-10-06 | 2022-03-03 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| MA41866A (fr) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
| EP3355923B1 (en) | 2015-10-01 | 2022-02-23 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Histone deacetylase inhibitors for use in the treatment of drug resistant melanoma |
| WO2017099591A1 (en) | 2015-12-07 | 2017-06-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment of inhibitor resistant braf-mutant cancers |
| WO2017204626A1 (en) | 2016-05-24 | 2017-11-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination therapy - combined map2k4/map3k1 and mek/erk inhibition |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5498720A (en) | 1993-08-26 | 1996-03-12 | Lee; An-Rong | Certain triazole compounds and their pharmaceutical uses |
| DE4438824A1 (de) * | 1993-10-16 | 1995-04-20 | Schering Ag | Triazolderivate, Verfahren zu deren Herstellung und deren Verwendung in Arzneimitteln |
| JP3542827B2 (ja) * | 1994-07-15 | 2004-07-14 | 帝国臓器製薬株式会社 | 新規な５−置換イソキサゾール−３−カルボン酸アミド誘導体 |
| US5470862A (en) * | 1995-02-03 | 1995-11-28 | Ohmeda Pharmaceutical Products Division Inc. | Substituted pyrazolyl compounds and methods employing such compounds |
| UA52698C2 (uk) * | 1996-10-04 | 2003-01-15 | Х. Луннбек А/С | Похідні (3-алкоксіізоксазол-4-іл)заміщеної 2-амінокарбонової кислоти та їх сірковмісні аналоги, фармацевтична композиція на їх основі |
| EP0927166A1 (en) * | 1997-02-14 | 1999-07-07 | Bayer Corporation | Amides as npy5 receptor antagonists |
| JP2002516325A (ja) * | 1998-05-26 | 2002-06-04 | スミスクライン・ビーチャム・コーポレイション | 新規な置換イミダゾール化合物 |
| JP4191825B2 (ja) * | 1998-09-10 | 2008-12-03 | あすか製薬株式会社 | ５−アミノイソキサゾール誘導体 |
| BR0104424A (pt) * | 2000-02-05 | 2002-01-08 | Vertex Pharma | Composições de pirazol úteis como inibidores de erk |
| WO2001056557A2 (en) | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of erk |
| DE602004012578T2 (de) * | 2003-08-15 | 2008-12-11 | Vertex Pharmaceuticals Inc., Cambridge | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen |
-
2001
- 2001-09-14 DE DE60122176T patent/DE60122176T2/de not_active Expired - Lifetime
- 2001-09-14 HU HU0302991A patent/HUP0302991A3/hu unknown
- 2001-09-14 CA CA002422376A patent/CA2422376A1/en not_active Abandoned
- 2001-09-14 AT AT01971002T patent/ATE335737T1/de not_active IP Right Cessation
- 2001-09-14 WO PCT/US2001/028790 patent/WO2002022610A1/en active IP Right Grant
- 2001-09-14 ZA ZA200301696A patent/ZA200301696B/en unknown
- 2001-09-14 JP JP2002526863A patent/JP4052573B2/ja not_active Expired - Fee Related
- 2001-09-14 NZ NZ525016A patent/NZ525016A/en unknown
- 2001-09-14 EP EP01971002A patent/EP1317453B1/en not_active Expired - Lifetime
- 2001-09-14 MX MXPA03002296A patent/MXPA03002296A/es not_active Application Discontinuation
- 2001-09-14 US US09/953,120 patent/US6495582B1/en not_active Expired - Lifetime
- 2001-09-14 IL IL15471001A patent/IL154710A0/xx unknown
- 2001-09-14 AU AU2001290940A patent/AU2001290940A1/en not_active Abandoned
- 2001-09-14 ES ES01971002T patent/ES2269458T3/es not_active Expired - Lifetime
-
2002
- 2002-10-15 US US10/272,622 patent/US6649640B2/en not_active Expired - Fee Related
-
2003
- 2003-03-14 NO NO20031192A patent/NO325089B1/no not_active IP Right Cessation
- 2003-07-16 HK HK03105158.4A patent/HK1052934B/zh not_active IP Right Cessation
- 2003-07-24 US US10/626,356 patent/US7354919B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1317453A1 (en) | 2003-06-11 |
| HUP0302991A3 (en) | 2009-10-28 |
| HK1052934A1 (en) | 2003-10-03 |
| ATE335737T1 (de) | 2006-09-15 |
| US7354919B2 (en) | 2008-04-08 |
| ES2269458T3 (es) | 2007-04-01 |
| NO20031192D0 (no) | 2003-03-14 |
| WO2002022610A1 (en) | 2002-03-21 |
| ZA200301696B (en) | 2004-04-28 |
| HK1052934B (zh) | 2007-01-12 |
| NO325089B1 (no) | 2008-01-28 |
| CA2422376A1 (en) | 2002-03-21 |
| HUP0302991A2 (hu) | 2003-12-29 |
| DE60122176T2 (de) | 2007-07-05 |
| JP4052573B2 (ja) | 2008-02-27 |
| DE60122176D1 (de) | 2006-09-21 |
| US20050090536A1 (en) | 2005-04-28 |
| NZ525016A (en) | 2004-10-29 |
| AU2001290940A1 (en) | 2002-03-26 |
| US6495582B1 (en) | 2002-12-17 |
| US6649640B2 (en) | 2003-11-18 |
| US20030195241A1 (en) | 2003-10-16 |
| NO20031192L (no) | 2003-05-13 |
| US20020177618A1 (en) | 2002-11-28 |
| IL154710A0 (en) | 2003-10-31 |
| JP2004509119A (ja) | 2004-03-25 |
| EP1317453B1 (en) | 2006-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1052934A1 (en) | Isoxazoles and their use as inhibitors of erk | |
| AU2002321910A1 (en) | Pyrazole-derived kinase inhibitors and uses thereof | |
| LT2001103A (en) | Pyrazole compositions useful as inhibitors of erk | |
| MXPA03009846A (es) | Derivados de triazol inhibidores de cinasa y usos de los mismos. | |
| WO2001056993A3 (en) | Pyrazole compositions useful as inhibitors of erk | |
| MXPA04001088A (es) | Derivados de pirazol como inhibidores de cinasa y uso de los mismos. | |
| WO2002088090A3 (en) | Pyrazole derived kinase inhibitors | |
| AP2003002853A0 (en) | Heterocyclic inhibitors of ERK2 and uses thereof | |
| BG108181A (en) | Novel spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | |
| MXPA03010961A (es) | Compuestos de tiazol utiles como inhibidores de proteinas cinasas. | |
| ATE339418T1 (de) | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen | |
| CY1112100T1 (el) | ΝΕΑ ΕΝΩΣΗ ΤΡΙΣΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ 8Η-ΠΥΡΙΔΟ[2,3-d]ΠΥΡΙΜΙΔΙΝ-7-ΟΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΑΣΘΕΝΕΙΩΝ, ΟΙ ΟΠΟΙΕΣ ΕΧΟΥΝ ΠΡΟΚΛΗΘΕΙ ΜΕ ΤΗ ΜΕΣΟΛΑΒΗΣΗ CSBP/p38 ΚΙΝΑΣΗΣ | |
| WO2001096298A3 (en) | 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase | |
| MXPA03009750A (es) | Compuestos quimicos. | |
| PT1268472E (pt) | Inibidores 3-aminopirazolicos de cinases dependentes da ciclina | |
| NO20024662L (no) | Prodroger av imidazopyridinderivater | |
| ATE287886T1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer | |
| DE60127131D1 (de) | Tricyclische imidazopyridine | |
| SE0003476D0 (sv) | Compounds | |
| BRPI0415390A (pt) | compostos de pirazinona substituìda para o tratamento da inflamação | |
| WO2002074735A3 (de) | Biurethanderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |